Disease reactivation after switching from natalizumab to daclizumab. [electronic resource]
Producer: 20180625Description: 2491-2494 p. digitalISSN:- 1432-1459
- Adult
- Anti-Inflammatory Agents -- therapeutic use
- Antibodies, Monoclonal, Humanized -- adverse effects
- Daclizumab
- Drug Substitution -- adverse effects
- Humans
- Immunoglobulin G -- adverse effects
- Immunologic Factors -- therapeutic use
- Magnetic Resonance Imaging
- Male
- Methylprednisolone -- therapeutic use
- Multiple Sclerosis, Relapsing-Remitting -- chemically induced
- Natalizumab -- therapeutic use
No physical items for this record
Publication Type: Case Reports; Journal Article; Observational Study
There are no comments on this title.
Log in to your account to post a comment.